API EUROPEAN GMP REQUIREMENTS · 2014-07-08 · Countries supplying APIs to Europe. API GMP...

Alessio Ferrari

API EUROPEAN GMP REQUIREMENTS

API GMP REQUIREMENTS

SUMMARY

GUIDELINES

IMPLICATIONS FOR THE INDUSTRY

ARTICLE 46 (F) OF DIRECTIVE 2001/83/EC

PART I EU GMP Chapter 5

OFFICIAL MEASURES TO PROTECT….

PROCEDURE TO REQUEST EU GMP

FUTURE TREND

GUIDELINES

2004/27/EC - Directive 2004/27/EC Amended by Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use (Official Journal L 136, 30/4/2004 p. 34 - 57).


GUIDELINES

Terms of the new directives (2004/27 for human health and2004/28 for animal health) call for inspections of API manufacturers,traders and brokers as well as “non-CEP APIs.”

Moreover, the directives are intended to focus on incoming-API aspects during inspections at dosage-form manufacturers and keep an eye out for the possibility of fraud and counterfeiting.


GUIDELINES

More specifically, under the new directives:

A qualified person must declare the API in compliance;

A GMP certificate from health authorities is not sufficient evidencethat the the GMP requirements are being met;

Guidelines require that an audit report be on file and available to regulators.


BEHIND THE GUIDELINES

The move was hailed by members of the European Fine Chemicals Group (EFCG), who called the directives a long time in the making and suggested that they are one way of ensuring that there is a level playing field for European API manufacturers.According to some estimates, more than 80% of APIs used in European pharmaceuticals now originate from China and India.EFCG estimates that there may be as many as 10,000 plants in theseCountries supplying APIs to Europe.


BEHIND THE GUIDELINES

“The health of the European consumer is at the crux of all this,”explained Cefic’s Tony Scott, who also serves as a member of theEFCG board. “The new law will make us trust the system.”


Implications for the Industry

“As a result of these new directives, pharmaceutical suppliers will nolonger be able to “just buy the API from a trader,” according to GuyVillax, president of Hovione and president of the EFCG pharmaceuticalbusiness committee.In fact, manufacturers must obtain a declaration and data to supportdirective compliance from the API producer.


Implications for the Industry

Audits of API producers will also occur more frequently and they will be performed by API users as well as third parties. These audit reports will be available to regulators and will cease to be confidential.Moreover, EFCG members are concerned that the EU member state health authorities may not be equipped to carry out the inspections called for under the new directive.“The industry is asking regulators…are they adequately equipped to regulate?”


The High Cost of Compliance

Although the new directives are aimed at ensuring the health of European consumers, they also go some way in maintaining the health of European API producers. According to the EFCG, GMP compliance increases a plant’s operating costs by 25%, reduces its flexibility and lengthens time to market.Although some may view the directives as direct attacks on the Indian and Chinese API market, EFCG noted that every company must abide by the same regulations, pointing out that “in Europe,some API company facilities are substandard and some in Asia are excellent. So who knows?”


Article 46 (f) of Directive 2001/83/EC

In accordance with Article 46 (f) of Directive 2001/83/EC as amended, manufacturing authorisation holders are required to use as starting materials only active substances which have been manufactured in accordance with the detailed guidelines on European Good Manufacturing Practice (GMP) for starting materials. Confirmation of compliance with the Regulation is required from the Qualified Person (QP) at the European site responsible for batch release (and/or site of finished product manufacture) for applications for new marketing authorisations, renewals and variations in which a change is proposed to the manufacturer of the active substance, finished product or site of batch release.


Article 46 bis (f) of Directive 2001/83/EC

“to comply with the principles and guidelines of good manufacturing practice for medicinal products and to use as starting materials only active substances, which have been manufactured in accordance with the detailed guidelines on European good manufacturing practice for starting materials.This point shall also be applicable to certain excipients, the list of which as well as the specific conditions of application shall be established by a Directive adopted by the Commission in accordance with the procedure referred to in Article 121(2).";


Part I EU GMP Chapter 5 Production Starting materials

5.25 The purchase of starting materials is an important operationwhich should involve staff who have a particular and thoroughknowledge of the suppliers5.26 Starting materials should only purchase from approvedsuppliers named in the relevant specifications and, wherepossible, directly from the producer. It is recommended that thespecifications established by the manufacturer for the startingmaterials be discussed with the suppliers…..omissis


HEPARINE GATE

FDA position:

US drug firms’qualification of overseas vendors will be subject to increased FDA scrutiny in the coming years.


MHRA- UK Medicines and Healthcare products Regulatory Agency

API Focused MHRA Inspections at Dosage Form Manufacturers

In this document the MHRA underlines the responsibilty of final dosage form manufacturers to assure that all APIs used for the manufacture of the medicinal products are manufactured according to GMP as defined in Part 2 of the EC GMP Guide (ICH Q7).


MHRA- UK Medicines and Healthcare products Regulatory Agency

API Focused MHRA Inspections at Dosage Form Manufacturers

The document the MHRA defines that “Manufacturing Authorisation holders must have a supplier evaluation and approval programme covering APIs (this must be in place irrespective of whether a QP declaration has been required, i.e. it applies to all existing drug products as well as new applications). This program must accumulate a body of evidence which enables the GMP compliance status of each API supplier to be determined. The programme must also include periodic re-evaluation of each supplier’s status.


Official Measures to Protect against Low-Quality APIs and Investigational MedicinalProducts Co-ordinated throughout Europe

Within the compilation of community procedures on inspections and exchange of information, on 9 July the EMEA published two documents describing measures for dealing with cases of serious GMP non-compliance or the suspension of a Certificate of Suitability (CEP) as well as the Europe-wide rapid alert system for these cases. The two documents bear the following titles:

Procedure for dealing with serious GMP non-compliance or voiding/suspension of CEPs thus requiring co-ordinated administrative actionProcedure for handling rapid alerts arising from quality defects.


http://www.emea.europa.eu/Inspections/docs/CoCP/2356709en.pdf



http://www.emea.europa.eu/Inspections/docs/CoCP/31351006enrev1.pdf

Official Measures to Protect against Low-Quality APIs and Investigational MedicinalProducts Co-ordinated throughout Europe

Both documents are directed at the supervisory- and registration authorities of the EC member states and stipulate a harmonised procedure for the rapid exchange of information and immediate actions to protect the public health from potentially dangerous, i.e. low-quality, active pharmaceutical ingredients (APIs) and medicinal products. This standardised procedure also includes the registration authorities of the individual countries, the EDQM and the EMEA itself.


Procedure for dealing with serious GMPnon-compliance or voiding/suspension of

CEPs...

If an inspector of a supervisory authority finds serious GMP deficiencies with potentially health-threatening consequences for the end user of pharmaceutical products when inspecting an API manufacturing site, in the report, he/she has to suggest measures as an appropriate reaction to the GMP deviations - if necessary also a rapid alert notification.


Procedure for dealing …..

These suggestions must be approved by the authorities of all EC member states. Should the site of an API manufacturer be partially or wholly in a state that is unacceptable from a GMP viewpoint, the following measures can come into consideration:

Withdrawal of the GMP certificate or issue of a GMP certificate with restricted scope Suspension of or refusal to grant a manufacturing authorisation Prohibition on supply Disciplinary measures against the Qualified Person Suspension of marketing authorisation Suspension of Certificate of Suitability (CEP)



These requirements can have highly unpleasant consequences for pharmaceutical manufacturers in Europe sourcing their APIs from third countries, like e.g. China. If e.g. a Chinese API manufacturer's CEP is voided for reasons of non-compliance, the marketing authorisation for the medicinal product is invalid on the condition that no other source has been indicated for the API. Validity is not restored until documents indicating a new API source are submitted within the framework of the variations procedure! In the past two months, a number of Chinese and Indian API

manufacturers lost their CEPs. We reported about this in our News of 1 July.


http://www.gmp-compliance.org/eca_news_1629_6094,6035,6105,6110_n.html

http://www.gmp-compliance.org/eca_news_1629_6094,6035,6105,6110_n.html


The suspension/voiding of a CEP falls within the competence of the EDQM, which also conducts inspections of API manufacturers. Even if a CEP has been suspended for other than GMP reasons, the authorities of all EC member states have to be notified. Then it is up to them to decide whether the quality, safety and efficacy of the products that are already on the market is affected.


Procedure for handling rapid alerts...

This standard operating procedure standardises the EU-wide rapid alert system and defines the following classification scheme for quality deficiencies:Class I: Potentially life-threatening or posing a serious risk to health. In any case, an EU-wide notification is required.Examples: Wrong product, label and contents are different; contamination with serious medical consequences; microbial contamination of parenterals or ophthalmics Class II: Illness or mistreatment are probable. If the product distribution is known, only the concerned authorities have to be notified. Examples: Missing or incorrect data on package leaflets; microbial contamination of non-parenteral sterile products; non-compliance with specifications


Procedure for handling rapid alerts...

Class III: Low risk to health, consequences improbable. Depending on the assessment of the issuing authority, the rapid alert system may be used.Examples: wrong or missing batch number; faulty closure; contamination with particulate matter.

These two standard operating procedures for the authorities of the EU member states aim to swiftly and efficiently co-ordinate effective measures against firms operating outside the binding GMP rules, to keep the European Market clear of APIs and investigational medicinal products of inferior quality and thus to reduce the risk to the end users' health. The two documents have not yet been adopted; however, it is of the utmost importance to be prepared for the forthcoming reinforced activities by supervisory authorities, EDQM and registration authorities.


GxP Inspections within the Centralised Procedure


Majority of Inspections Sector operations are related to applications submitted to the EMEA (centralised procedures, pre&postauthorisation and referrals)EMEA co-ordinates Inspection activities within the agreed timetable,There are no inspectors at the EMEA, we use the expertise of the EU

Member States

Co-ordination of Pre-authorisation:GMP Inspections

in order to complete the assessment process.Legal basis: Article 8.2 (or 30.2 for vet medicinal products) Council Regulation 726/2004.Responsibility for carrying out inspections rests with the Supervisory AuthoritySupervisory Authority which is defined as the Competent Authority of the MS in whichthe product is either manufactured or imported within the EEA.


COUNCIL REGULATION 726/2004(CAP/EMEA)

ART 57...THE AGENCY SHALL UNDERTAKETHE FOLLOWING TASKS WITHIN ITSCOMMITTEES:

i) co-ordinating the verification of compliance with theprinciples of good manufacturing practice, good laboratorypractice and good clinical practice and the verification ofcompliance with pharmacovigilance obligations


Co-ordination of GMP Inspections

Type of inspections:

GMP:- For sites located in third countries , where EU-GMP isunconfirmed (no satisfactory EU inspection in the last 2years on same building, similar type of product andequipment.Product & Process:To assess Quality issues raised by Rapp/CoRapp duringassessment of Part II of the application.Can apply to all sites wherever they are located(EEA/Third countries)



Timetable for Inspections


Shorter timetables

Some procedures have shorter timetables;

Generic Applications

Applications granted accelerated assessment

• If inspection requested during the assessment then there will be a clock stop and secondary evaluation phase


Composition of Inspection Teams

Inspection team:

Leading inspector(s)Scientific experts appointed on the advice of the Rapporteur and

or Co-Rapporteur.

Number of inspectors:

– Normally two inspectors– Higher numbers may be justified.


Fees

Council Regulation 297/95 specifies fees payable for inspectionsImplementing rules for Council Regulation adopted by EMEA

management Board set the level of the fees.Inspection fee per site inspected, and sub-divided between

EMEA and inspectorates;For 3rd country inspections, travel expenses etc. are payable

separately.

DON’T FORGET TO APPLY FOR YOUR FEEREDUCTION


GMP Inspections Information in theDossier

Part 1A Application FormAnnexes – manufacturing licences, GMPCertificates, QP Declaration.Module 3.


Common Dossier Validation ProblemsManufacturing Authorisations

Site not licensedSite has IMP LicenceLicence does not include activities to be performed.Inconsistent manufacturing/testing site information throughout dossier

QP DeclarationsQP cannot provide declaration.Declaration does not cover all drug substancemanufacturing sitesDeclaration not signed by QP or by all QP’s

Testing upon importation


Post-Authorisation GMP InspectionsCo-ordination of GMP inspections during post authorisation

procedures

Variations, Line extension

Co-ordination of for cause inspections

GMP ProblemsQuality Defects


Post-Authorisation GMP InspectionsCo-ordination of routine GMP inspections

The EMEA prepares a program of re-inspections in ThirdCountries (TC) for centralised products.

Re-inspections are also adopted by the CxMP.

MSs may provide feedback on the program (e.g. delegation, assistance from another MS, combination with national products).

Inspections are carried out at least every 2-3 years, unless a morefrequent basis is recommended by the inspectors.

DISPONIBILIDAD DEL MATERIAL DE LAS CONFERENCIAS

http://www.latconsultores.com.ar/novedades

[email protected]

Alessio Ferrari

THANKS FOR YOUR ATTENTION

Date post:	02-Aug-2020
Category:	Documents
Upload:	others
View:	9 times
Download:	0 times

API EUROPEAN GMP REQUIREMENTS · 2014-07-08 · Countries supplying APIs to Europe. API GMP...

Documents